Genetically Modifying CAR T Cells Using a CRISPR-Cas9 System

JoVE Encyclopedia of Experiments

Immunology

0 weergaven • 2:55 min • July 8th, 2025

$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Begin with a suspension of T cells and treat them with CAR lentiviruses carrying a gene for the chimeric antigen receptor or CAR and CRISPR lentiviruses.

The CRISPR lentivirus contains genes for the guide RNA and Cas9 nuclease as well as an antibiotic resistance gene.

Both the CAR and CRISPR lentiviruses interact with T cells and release their RNA.

These RNAs are reverse-transcribed and converted into corresponding DNA, which integrates into the T cell DNA.

This enables the synthesis of CAR proteins, guide RNAs, and Cas9 proteins.

The guide RNA forms a complex with Cas9, which specifically recognizes and binds to the target gene on the T cell DNA.

Meanwhile, Cas9 cleaves the DNA, creating a double-stranded break.

This break is repaired via non-homologous end joining, an error-prone repair mechanism, resulting in target gene modification.

This generates genetically modified T cells with chimeric antigen receptors.

Treat the cells with antibiotics to eliminate the unmodified T cells and selectively isolate the genetically modified CAR T cells.

To disrupt granulocyte-macrophage colony-stimulating factor, utilize a guide RNA, as described in the manuscript. Incubate transfection reagents at room temperature for 30 minutes. After incubation, add them to the 293T cells that have reached 70% to 90% confluency, and culture the transfected cells at 37 degrees Celsius, 5% CO2 to produce lentivirus.

At 24 and 48 hours, harvest, and concentrate virus-containing supernatant by ultracentrifugation in 50-milliliter ultracentrifuge tubes, and freeze at minus 80 degrees Celsius for future use. Then, on day one, gently resuspend the T cells to break up rosettes.

In a BSL-2 plus approved laboratory, to generate CAR T cells, add CAR19 lentivirus and GM-CSF-targeting CRISPR lentivirus to the stimulated T cells. On day three and day five, for successfully transduced lenti-CRISPR-edited T cells carrying puromycin resistance, treat cells with puromycin dihydrochloride at a concentration of 1 microgram of puromycin per milliliter.

12:16

Een Syngeneic B-cel lymfoom muismodel voor pre-klinische evaluatie van CD19 auto T cellen

Gerelateerde video's

0 Bekeken

06:33

Productie van menselijke CRISPR-engineered CAR-T-cellen

Gerelateerde video's

0 Bekeken

14:49

Toepassing van CRISPR-interferentie (CRISPRi) voor genuitschakeling bij pathogene soorten leptospira

Gerelateerde video's

0 Bekeken

02:30

A CRISPR-Cas9 Technique for Gene Editing in T Cells

Gerelateerde video's

0 Bekeken

09:29

Klinische toepassing van Sleeping Beauty En Kunstmatige antigeen presenterende cellen genetisch te wijzigen T-cellen uit perifeer en navelstrengbloed

Gerelateerde video's

0 Bekeken

10:21

Met behulp van CRISPR/Cas9 Gene bewerken om te onderzoeken de oncogene activiteit van Mutant Calreticulin in Cytokine afhankelijke hematopoietische cellen

Gerelateerde video's

0 Bekeken

09:51

Verbeterde genoom bewerken met Cas9 Ribonucleoprotein in verschillende cellen en organismen

Gerelateerde video's

0 Bekeken

07:20

Generatie van Knock-out primaire en uitgebreide menselijke NK-cellen met behulp van Cas9 Ribonucleoproteins

Gerelateerde video's

0 Bekeken

07:56

CRISPR/Cas9 gebruiken om GM-CSF uit te nemen in CAR-T-cellen

Gerelateerde video's

0 Bekeken

10:29

Generatie van menselijke chimere antigeenreceptorregulerende T-cellen

Gerelateerde video's

0 Bekeken

Laatst bijgewerkt: 22 augustus 2026